摘要
目的 研究普乐可复 (FK5 0 6 )对肾移植患者免疫抑制作用的疗效与安全性。方法 肾移植术后应用FK5 0 6免疫抑制治疗 82例 ,分为临床验证组 42例和切换治疗组 40例。结果 临床验证组有 40例 (95 .2 % )肾功能在 14d内恢复正常 ,1例 (2 .4% )发生急性排斥反应 ,经治疗逆转。切换治疗组有 2 4例肝功能逐渐恢复正常 ;3例移植肾发生急性肾小管坏死 (ATN)伴急性排斥反应 ,6例发生慢性排斥反应 ,4例发生难治性排斥反应 ,均经治疗后逆转 ;2例严重齿龈增生经治疗完全消退 ;1例腹痛消失。结论 FK5 0 6是一种安全高效的免疫抑制剂 ,排斥反应发生率低 ,毒副作用少 ,可与环孢素A(CsA)相媲美。对于难治性和慢性排斥反应、严重肝功能损害和牙龈增生等患者切换FK5 0 6治疗 ,是一种较好的方法。
Objective To investigate the immunosuppressive effect and safety of FK506 for renal transplant recipients.Methods FK506 had been used as a postoperative immunosuppressant for 82 cases of renal transplantation. Among them, 42 cases were included in clinical checking group and 40 cases served as conversion groups. Results In the clinical checking group, renal function in 40 cases (95.2%) returned normal within 14 days. Acute rejection episode occurred in one case, but recovered after treatment (2.4%). In the conversion group, liver function of 24 cases gradually returned normal. ATN accompanied with acute rejection occurred in 3 cases, chronic rejection in 6 cases and knotty rejection in 4 cases. All of them were reversed after treatment. Two cases of severe gingival hyperplasia recovered completely and one case of abdomen pain subsided.Conclusions FK506 is a safe and effective immunosuppressant, and has a low incidence of rejection and less toxicity. It may be compared favorably with CsA. It might be a better measure for FK506 treating knotty and chronic rejection, severe liver function damage, gingival hyperplasia.
出处
《中华器官移植杂志》
CAS
CSCD
2000年第2期119-121,共3页
Chinese Journal of Organ Transplantation
